Proton Beam Therapy (PBT) Clinical Coverage Criteria
Customize your policy alerts
Sign up for all fallon_community_health_plan_inc policy alerts
Know when fallon_community_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage criteria and prior authorization requirements for proton beam therapy applied to Fallon Health products, including Medicare Advantage, MassHealth, NaviCare, PACE, and Community Care members.
Effective for dates of service on or after September 1, 2024, Fallon Health will use InterQual® Criteria when making medical necessity determinations for proton beam therapy.
New sections describing Medicare Variation and MassHealth Variation were added to clarify applicability of external Medicare LCDs/NCDs and MassHealth guidance.
Prior authorization is required for proton beam therapy across listed Fallon Health products.
Coverage and Medical Necessity Criteria
Medical necessity
Covered when InterQual® Criteria for Proton Beam Radiotherapy are met and required documentation is provided.
InterQual-based coverage and documentation
Required documentation (all required)
- Support one or more indications as described in InterQual® Criteria.
- Include a treatment prescription defining treatment goals, with specific dose–volume parameters for target and nearby critical structures, and beam delivery details (method of beam modulation, field arrangement, expected positional and range uncertainties).
- Include a physician-signed treatment plan that meets the prescribed dose–volume parameters for the clinical target volume and surrounding organs at risk in the presence of expected uncertainties.
- Describe the target setup verification methodology, including patient positioning, immobilization, image guidance and frequencies.
- Include verification of the planned dose distribution via independent dose calculation or physical measurement.
Failure to obtain prior authorization may result in denial of coverage for Fallon Health products.
This policy identifies proton beam therapy as an area requiring continued evidence development for certain indications. As noted in the Exclusions section, these indications are not considered established for routine coverage and remain subject to investigational status pending additional comparative clinical evidence.
The policy specifically lists the following disease sites as requiring continued evidence development and therefore excluded from routine coverage at this time: breast cancer, esophageal cancer, gastric cancer, gynecologic cancer, and lung cancer.
Billing and Code Reference
Provider Requirements and Authorization Actions
Prior authorization required; InterQual® PBRT is the medical necessity source
Prior authorization is required for proton beam therapy. Fallon Health uses InterQual® CP: Procedures, Proton Beam Radiotherapy (PBRT) and the Pediatric PBRT criteria as the medical necessity standard effective for dates of service on or after September 1, 2024.
- Applies to listed Fallon Health products (Medicare Advantage, MassHealth ACO, NaviCare, PACE, Community Care).
- InterQual® criteria referenced: InterQual CP: Procedures, Proton Beam Radiotherapy and Pediatric PBRT.
No step therapy requirements
No step therapy requirements are specified in this policy for proton beam therapy.
Required medical record documentation to support InterQual® indications
Medical record documentation must support one or more InterQual® indications and include detailed treatment and verification information to allow medical necessity determination.
- Support one or more indications as described in InterQual® Criteria.
- Treatment prescription with specific dose-volume parameters for target and nearby critical structures and beam delivery details (modulation method, field arrangement, expected positional and range uncertainties).
- Physician-signed treatment plan meeting prescribed dose-volume parameters for the clinical target volume and organs at risk given expected uncertainties.
- Description of target setup verification methodology (patient positioning, immobilization, image guidance and frequencies).
- Verification of planned dose distribution via independent dose calculation or physical measurement.
Denial risk if prior authorization not obtained
Failure to obtain required prior authorization for proton beam therapy may result in denial of coverage for Fallon Health products.
Background and Rationale
Proton beam therapy (PBT) is an external beam radiation modality that deposits the majority of particle energy at a characteristic distal region (the Bragg peak), which can allow higher tumor dose delivery with potentially reduced exposure to surrounding normal tissues compared with conventional photon-based techniques. Because of these physical and dosimetric properties, PBT may offer clinical advantages when sparing adjacent normal structures is important; however, the policy emphasizes that appropriate use for many disease sites remains subject to ongoing evidence development and comparative effectiveness evaluation.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.